Obesity Treatment Moving Toward Fragmented Clinical Approaches

The obesity market is on the verge of new product introductions (especially drugs) and will soon become more fragmented by treatment options and competitors.  The FDA has relented in the drug front, making it likely in the next 1-2 years (as we predicted) that the market will be split among appetite suppression, malabsorption, satiey and combination drugs.  The trend is equally strong in the device arena, where the market dominance of restrictive devices (e.g., Lap-Band) will cede to artificial fullness, malabsorption, gastric emptying, and appetite suppression devices.

The obesity market is on the verge of new product introductions (especially drugs) and will soon become more fragmented by treatment options and competitors.  The FDA has relented in the drug front, making it likely in the next 1-2 years (as we predicted) that the market will be split among appetite suppression, malabsorption, satiey and combination drugs.  The trend is equally strong in the device arena, where the market dominance of restrictive devices (e.g., Lap-Band) will cede to artificial fullness, malabsorption, gastric emptying, and appetite suppression devices.

Below is illustrated the balance of the drug and device markets by type of obesity product.

Balance of Obesity Drugs and Device Markets by Type 2009-2019

Source: “Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019″, Report #S835, MedMarket Diligence, LLC.

Of course, another way to view the obesity market that is supported by the general trend of clinical treatment options competing against each other irrespective of technology type is that the aggregate obesity market is comprised of a shifting balance among device and drug options.  In any case, below is illustrated the relative balance of all drug and device markets for the treatment of obesity.

Balance of All Obesity Drugs and Device Markets by Type 2009-2019

Source: “Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019″, Report #S835, MedMarket Diligence, LLC.